Build status - In Progress

A multi-center double-blind placebo-controlled Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patients self-reported symptoms and their impacts

Recruiting
99 years or below
All
Phase 4
4 participants needed
1 Location

Brief description of study

This is a prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, exploratory Phase 4 study. The purpose is to identify the effect of selexipag on daily life physical activity assessed by a wearable device in patients with PAH (WHO Group 1). Approximately 100 patients will be enrolled in the study at 45 sites in 12 countries.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 829514

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center